US FDA finds widely used asthma drug impacts the brain | Reuters
Excerpt from Reuters: “U.S. government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co (MRK.N), opens new tab may be linked to serious mental health problems for some patients, according to a scientific presentation reviewed by Reuters.
The researchers found that the drug, sold under the brand name Singulair and generically as montelukast, attaches to multiple brain receptors critical to psychiatric functioning.” Read more.
Popular anxiety drug being recalled nationwide for ‘possibly life-threatening’ error | New York Post
Excerpt from the New York Post: “The Pennsylvania-based drug maker Endo announced this week that it is expanding its recall of clonazepam tablets because some cartons bear the incorrect drug strength and wrong drug code.
The new recall affects 16 lots of Clonazepam Orally Disintegrating Tablets, USP (C-IV), with doses ranging from 0.125 milligrams to 2 milligrams.” Read more.
Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback | Reuters
Excerpt from Reuters: “Lexicon Pharmaceuticals (LXRX.O), opens new tab said on Friday it would reduce its workforce by about 60%, after the U.S. Food and Drug Administration noted deficiencies in its application seeking approval for its diabetes drug.” Read more.
Sorry, the comment form is closed at this time.